

Sarinya Kongpetch

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2283050/publications.pdf>

Version: 2024-02-01

21
papers

1,086
citations

687363

13
h-index

713466

21
g-index

22
all docs

22
docs citations

22
times ranked

2037
citing authors

#	ARTICLE	IF	CITATIONS
1	Therapeutic targeting of ARID1A and PI3K/AKT pathway alterations in cholangiocarcinoma. PeerJ, 2022, 10, e12750.	2.0	5
2	Licochalcone A Induces Cholangiocarcinoma Cell Death Via Suppression of Nrf2 and NF- κ B Signaling Pathways. Asian Pacific Journal of Cancer Prevention, 2022, 23, 115-123.	1.2	2
3	Inhibition of FGFR2 enhances chemosensitivity to gemcitabine in cholangiocarcinoma through the AKT/mTOR and EMT signaling pathways. Life Sciences, 2022, 296, 120427.	4.3	14
4	All-trans-retinoic acid induces RAR β -dependent apoptosis via ROS induction and enhances cisplatin sensitivity by NRF2 downregulation in cholangiocarcinoma cells. Oncology Letters, 2022, 23, 179.	1.8	6
5	Epidermal growth factor receptor as a potential target of momordin Ic to promote apoptosis of cholangiocarcinoma cells. Journal of Pharmacy and Pharmacology, 2022, 74, 996-1005.	2.4	1
6	Targeting FGFR inhibition in cholangiocarcinoma. Cancer Treatment Reviews, 2021, 95, 102170.	7.7	85
7	Derrisichalcone suppresses cholangiocarcinoma cells through targeting ROS-mediated mitochondrial cell death, Akt/mTOR, and FAK pathways. Naunyn-Schmiedeberg's Archives of Pharmacology, 2021, 394, 1929-1940.	3.0	3
8	Cucurbitacin B Diminishes Metastatic Behavior of Cholangiocarcinoma Cells by Suppressing Focal Adhesion Kinase. Asian Pacific Journal of Cancer Prevention, 2021, 22, 219-225.	1.2	4
9	Targeted Modulation of FAK/PI3K/PDK1/AKT and FAK/p53 Pathways by Cucurbitacin B for the Antiproliferation Effect Against Human Cholangiocarcinoma Cells. The American Journal of Chinese Medicine, 2020, 48, 1475-1489.	3.8	18
10	Phenformin inhibits proliferation, invasion, and angiogenesis of cholangiocarcinoma cells via AMPK-mTOR and HIF-1A pathways. Naunyn-Schmiedeberg's Archives of Pharmacology, 2020, 393, 1681-1690.	3.0	12
11	Lack of Targetable FGFR2 Fusions in Endemic Fluke-Associated Cholangiocarcinoma. JCO Global Oncology, 2020, 6, 628-638.	1.8	35
12	Cucurbitacin B induces mitochondrial-mediated apoptosis pathway in cholangiocarcinoma cells via suppressing focal adhesion kinase signaling. Naunyn-Schmiedeberg's Archives of Pharmacology, 2019, 392, 271-278.	3.0	13
13	Metformin sensitizes cholangiocarcinoma cell to cisplatin-induced cytotoxicity through oxidative stress mediated mitochondrial pathway. Life Sciences, 2019, 217, 155-163.	4.3	20
14	Myricetin ameliorates cytokine-induced migration and invasion of cholangiocarcinoma cells via suppression of STAT3 pathway. Journal of Cancer Research and Therapeutics, 2019, 15, 157.	0.9	18
15	Metformin enhances cisplatin induced inhibition of cholangiocarcinoma cells via AMPK-mTOR pathway. Life Sciences, 2018, 207, 172-183.	4.3	29
16	Downregulation of NAD(P)H:quinone oxidoreductase 1 inhibits proliferation, cell cycle and migration of cholangiocarcinoma cells. Oncology Letters, 2017, 13, 4540-4548.	1.8	19
17	Whole-Genome and Epigenomic Landscapes of Etiologically Distinct Subtypes of Cholangiocarcinoma. Cancer Discovery, 2017, 7, 1116-1135.	9.4	637
18	Genetics of Opisthorchis viverrini-related cholangiocarcinoma. Current Opinion in Gastroenterology, 2015, 31, 258-263.	2.3	45

#	ARTICLE	IF	CITATIONS
19	Pathogenesis of cholangiocarcinoma: From genetics to signalling pathways. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2015, 29, 233-244.	2.4	34
20	Fumarate Hydratase-deficient Cell Line NCCFH1 as a New In Vitro Model of Hereditary Papillary Renal Cell Carcinoma Type 2. <i>Anticancer Research</i> , 2015, 35, 6639-53.	1.1	14
21	Crucial Role of Heme Oxygenase-1 on the Sensitivity of Cholangiocarcinoma Cells to Chemotherapeutic Agents. <i>PLoS ONE</i> , 2012, 7, e34994.	2.5	71